Depression, survival, and epidermal growth factor receptor genotypes in patients with metastatic non-small cell lung cancer

Palliative and Supportive Care

Volumn 11, Issue 3, 2013, Pages 223-229

  Pirl, William F ^a   Traeger, Lara ^a   Greer, Joseph A ^a   Jackson, Vicki ^a   Lennes, Inga T ^a   Gallagher, Emily ^a   Sequist, Lecia ^a   Temel, Jennifer S ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

Depression; EGFR mutation; Lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

AGED; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; GENETICS; GENOTYPE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DEPRESSION; FEMALE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE;

EID: 84880129708     PISSN: 14789515     EISSN: 14789523     Source Type: Journal    
DOI: 10.1017/S1478951512001071     Document Type: Review

References (44)

1. Azzoli, C.G., Baker, S., Jr., Temin, S., et al. (2009). American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-smallcell lung cancer. Journal of Clinical Oncology, 27, 6251-6266.
2. Bezjak, A., Tu, D., Seymour, L., et al. (2006). Symptom improvement in lung cancer patients treated with erlotinib: Quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology, 24, 3831-3837.
3. Borrell-Pages, M., Rojo, F., Albanell, J., et al. (2003). TACE is required for the activation of the EGFR by TGF-alpha in tumors. EMBO Journal, 22, 1114-1124.
4. Dias-Santagata, D., Akhavanfard, S., David, S.S., et al. (2010). Rapid targeted mutational analysis of human tumours: A clinical platform to guide personalized cancer medicine. EMBO Molecular Medicine, 2, 146-158.
5. Eberhard, D.A., Johnson, B.E., Amler, L.C., et al. (2005). Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. Journal of Clinical Oncology, 23, 5900-5909.
6. Ell, K., Xie, B., Quon, B., et al. (2008). Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. Journal of Clinical Oncology, 26, 4488-4496.
7. Fann, J.R., Berry, D.L.,Wolpin, S., et al. (2009). Depression screening using the Patient Health Questionnaire-9 administered on a touch screen computer. Psycooncology, 18, 14-22.
8. Fukuoka, M.,Wu, Y.L., Thongprasert, S., et al. (2011). Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). Journal of Clinical Oncology, 29, 2866-2874
9. Fukuyama, T., Ichiki, Y., Yamada, S., et al. (2007). Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Science, 98, 1048-1054.
10. Gilbert, J. & Davis, F.C. (2009). Behavioral effects of systemic transforming growth factor-alpha in Syrian hamsters. Behavioural Brain Research, 198, 440-448.
11. Gross, A.L., Gallo, J.J. & Eaton, W.W. (2010). Depression and cancer risk: 24 years of follow-up of the Baltimore Epidemiologic Catchment Area sample. Cancer Causes & Control, 21, 191-199.
12. Iurisci, I., Rich, T., Levi, F., et al. (2007). Relief of symptoms after gefitinib is associated with improvement of rest/ activity rhythm in advanced lung cancer. Journal of Clinical Oncology, 25, e17-19.
13. Jehn, C.F., Kuehnhardt, D., Bartholomae, A., et al. (2006). Biomarkers of depression in cancer patients. Cancer, 107, 2723-2729.
14. Knekt, P., Raitasalo, R., Heliovaara, M., et al. (1996). Elevated lung cancer risk among persons with depressed mood. American Journal of Epidemiology, 144, 1096-1103.
15. Kramer, A., Yang, F.C., Snodgrass, P., et al. (2001). Regulation of daily locomotor activity and sleep by hypothalamic EGF receptor signaling. Science, 294, 2511-2515.
16. Lutgendorf, S.K.,Weinrib, A.Z., Penedo, F., et al. (2008). Interleukin- 6, cortisol, and depressive symptoms in ovarian cancer patients. Journal of Clinical Oncology, 26, 4820-4827.
17. Masago, K., Fujita, S., Hatachi, Y., et al. (2008). Clinical significance of pretreatment serum amphiregulin and transforming growth factor-alpha, and an epidermal growth factor somatic mutation in patients with advanced non-small cell lung cancer. Cancer Science, 99, 2295-2301.
18. Miller, A.H., Ancoli-Israel, S., Bower, J.E., et al. (2008). Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. Journal of Clinical Oncology, 26, 971-982.
19. Mok, T.S., Wu, Y.L., Thongprasert, S., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361, 947-957.
20. Musselman, D.L., Miller, A.H., Porter, M.R., et al. (2001). Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. American Journal of Psychiatry, 158, 1252-1257.
21. National Lung Screening Trial Research Team, Aberle, D.R., Adams, A.M., et al. (2011). Reduced lung-cancer mortality with low-dose computed tomographic scanning. New England Journal of Medicine, 365, 395-409.
22. Normanno, N., DeLuca, A., Bianco, C., et al. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, 366, 2-16.
23. Onitilo, A.A., Nietert, P.J. & Egede, L.E. (2006). Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. General Hospital Psychiatry, 28, 396-402.
24. Paralkar, V.R., Li, T. & Langer, C.J. (2008). Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: A Fox Chase Cancer Center retrospective. Clinical Lung Cancer, 9, 116-121.
25. Pinquart, M. & Duberstein, P.R. (2010). Depression and cancer mortality: a meta-analysis. Psychological Medicine, 40, 1797-1810.
26. Pirl, W.F., Temel, J.S., Billings, J.A., et al. (2008). Depression after diagnosis of non-small cell lung cancer and survival: A pilot study. Psychosomatics, 49, 218-224.
27. Pirl, W.F., Traeger, L., Greer, J.A., et al. (2011). Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer. Oncologist, 16, 1299-1306.
28. Pirl,W.F., Traeger, L., Greer, J.A., et al. (2012). Depression and survival in metastatic NSCLC: impact of early palliative care. Journal of Clinical Oncology, 30, 1310-1315.
29. Rich, T.A. (2007). Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis. Journal of Supportive Oncology, 5, 167-174.
30. Rich, T.A., Innominato, P.F., Boerner, J., et al. (2005). Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour restactivity patterns in patients with metastatic colorectal cancer. Clinical Cancer Research, 11, 1757-1763.
31. Satin, J.R., Linden, W. & Phillips, M.J. (2009). Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer, 115, 5349-5361.
32. Sequist, L.V., Bell, D.W., Lynch, T.J., et al. (2007a). Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Journal of Clinical Oncology, 25, 587-595.
33. Sequist, L.V., Heist, R.S., Shaw, A.T., et al. (2011). Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology, 22, 2616-2624.
34. Sequist, L.V., Joshi, V.A., Jänne, P.A., et al. (2007b). Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist, 12, 90-98.
35. Snodgrass-Belt, P., Gilbert, J.L. & Davis, F.C. (2005). Central administration of transforming growth factoralpha and neuregulain-1 suppress active behaviors and cause weight loss in hamsters. Brain Research, 1038, 171-182.
36. Spitzer, R.L., Kroenke, K. & Williams, J.B.W. (1999). Validation and utility of a self-report version of PRIME-MD: The PHQ primary care study. Journal of the American Medical Association, 282, 1737-1744.
37. Su, C, Zhou, C., Zhou, S. & Xu, J. (2010). Serum cytokine levels in patients with advanced non-small cell lung cancer: Correlation with treatment response and survival. Medical Oncology, 28, 1453-1457.
38. Stinchcombe, T.E. & Socinski, M.A. (2009). Current treatments for advanced non-small cell lung cancer. Proceedings of the American Thoracic Society, 6, 233-241.
39. Temel, J.S., Greer, J.A., Muzikansky, A., et al. (2010) Early palliative care for patients with metastatic non-small cell lung cancer. New England Journal of Medicine, 363, 733-742.
40. Tracy, S., Mukohara, T., Hansen, M., et al. (2004). Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Research, 64, 7241-7244.
41. Vadigepalli, R., Hao, H., Miller, G.M., et al. (2006). Epidermal growth factor receptor-induced circadian-time-dependent gene regulation in suprachiasmatic nucleus. Neuroreport, 17, 1437-1441.
42. Volante, M., Saviozzi, S., Rapa, I., et al. (2007). Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer. Cancer, 110, 1321-1328.
43. Wang, X.S., Shi, Q.,Williams, L.A., et al. (2010). Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain, Behavior, and Immunity, 24, 968-974.
44. Yonesaka, K., Zejnullahu, K., Lindeman, N., et al. (2008). Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wildtype cancers. Clinical Cancer Research, 14, 6963-6973.